Literature DB >> 30023126

Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma.

Yasuo Hamamoto1.   

Abstract

Entities:  

Year:  2018        PMID： 30023126      PMCID： PMC6036051          DOI： 10.21037/jtd.2018.05.37

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

2.  Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Authors:  Toshihiro Kudo; Yasuo Hamamoto; Ken Kato; Takashi Ura; Takashi Kojima; Takahiro Tsushima; Shuichi Hironaka; Hiroki Hara; Taroh Satoh; Satoru Iwasa; Kei Muro; Hirofumi Yasui; Keiko Minashi; Kensei Yamaguchi; Atsushi Ohtsu; Yuichiro Doki; Yuko Kitagawa
Journal:  Lancet Oncol       Date:  2017-03-15       Impact factor: 41.316

3.  Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.

Authors:  Hideharu Kimura; Takashi Sone; Akari Murata; Hayato Koba; Yuichi Tambo; Johsuke Hara; Miki Abo; Kazuo Kasahara
Journal:  Lung Cancer       Date:  2017-02-23       Impact factor: 5.705

4.  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors:  Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

5.  Factors affecting cytokine change after esophagectomy for esophageal cancer.

Authors:  Akihiko Okamura; Hiroya Takeuchi; Satoru Matsuda; Masaharu Ogura; Taku Miyasho; Rieko Nakamura; Tsunehiro Takahashi; Norihito Wada; Hirofumi Kawakubo; Yoshiro Saikawa; Yuko Kitagawa
Journal:  Ann Surg Oncol       Date:  2015-01-09       Impact factor: 5.344

6.  Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

Authors:  Toshihiko Doi; Sarina A Piha-Paul; Shadia I Jalal; Sanatan Saraf; Jared Lunceford; Minori Koshiji; Jaafar Bennouna
Journal:  J Clin Oncol       Date:  2017-11-08       Impact factor: 44.544

7.  Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Authors:  Gustavo Schvartsman; S Andrew Peng; Giorgios Bis; J Jack Lee; Marcelo F K Benveniste; Jianjun Zhang; Emily B Roarty; Lara Lacerda; Stephen Swisher; John V Heymach; Frank V Fossella; William N William
Journal:  Lung Cancer       Date:  2017-08-03       Impact factor: 5.705

8.  Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

Authors:  F Stephen Hodi; Marcus Ballinger; Benjamin Lyons; Jean-Charles Soria; Mizuki Nishino; Josep Tabernero; Thomas Powles; David Smith; Axel Hoos; Chris McKenna; Ulrich Beyer; Ina Rhee; Gregg Fine; Nathan Winslow; Daniel S Chen; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2018-01-17       Impact factor: 44.544

9.  Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.

Authors:  Georgia Ritchie; Harry Gasper; Johnathan Man; Sally Lord; Ian Marschner; Michael Friedlander; Chee Khoon Lee
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

10.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

Authors:  Koji Haratani; Hidetoshi Hayashi; Yasutaka Chiba; Keita Kudo; Kimio Yonesaka; Ryoji Kato; Hiroyasu Kaneda; Yoshikazu Hasegawa; Kaoru Tanaka; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.